Entero Therapeutics, Inc. Sample Contracts
PRE-FUNDED COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC.Security Agreement • March 15th, 2023 • First Wave BioPharma, Inc. • Pharmaceutical preparations
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ___________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation (the “Company”), up to _____ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT ENTERO THERAPEUTICS, INC.Common Stock Purchase Warrant • July 11th, 2024 • Entero Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ___________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval Date (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the date that is the fifth (5th) anniversary of the Stockholder Approval Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Entero Therapeutics, Inc. a Delaware corporation (the “Company”), up to 3,525,348 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 13th, 2024 • First Wave BioPharma, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 10, 2024, between First Wave BioPharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 15th, 2023 • First Wave BioPharma, Inc. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of March __, 2023, by and between First Wave BioPharma, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
UNDERWRITING AGREEMENT among AZURRX BIOPHARMA, INC. and WALLACHBETH Capital, LLC and NETWORK 1 FINANCIAL SECURITIES, INC.,Underwriting Agreement • October 14th, 2016 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
The undersigned, AzurRx BioPharma, Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) and set forth on Schedule 4 attached hereto, as being subsidiaries or affiliates of AzurRx BioPharma, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the Underwriters named in Schedule I hereto (the “Representatives” and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 15th, 2023 • First Wave BioPharma, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March __, 2023, between First Wave BioPharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
AzurRx Biopharma, Inc. 9,090,910 Shares of Common Stock (par value $0.0001 per share) Amended and Restated Underwriting AgreementUnderwriting Agreement • July 27th, 2021 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
AzurRx Biopharma, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 9,090,910 shares of its common stock, par value $0.0001 per share (the “Shares”). The 9,090,910 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,363,636 Shares as provided in Section 2. The additional 1,363,636 Shares that may be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares, are collectively called the “Offered Shares.” H.C. Wainwright & Co., LLC (“Wainwright”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To
SERIES E COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC.Warrant Agreement • September 22nd, 2022 • First Wave BioPharma, Inc. • Pharmaceutical preparations • New York
THIS SERIES E COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [ ], 2022 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on _______1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PRE-FUNDED COMMON STOCK PURCHASE WARRANT ENTERO THERAPEUTICS, INC.Pre-Funded Common Stock Purchase Warrant • May 12th, 2025 • Entero Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Entero Therapeutics, Inc., a Delaware corporation (the “Company”), up to [·] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock (as defined herein). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, INC.Common Stock Purchase Warrant • May 13th, 2024 • First Wave BioPharma, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ______ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May 14, 2024 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on May 14, 2030 (the “Termination Date”) but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc. a Delaware corporation (the “Company”), up to _______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 14th, 2019 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • Illinois
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 13, 2019, by and between AZURRX BIOPHARMA, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
SENIOR CONVERTIBLE NOTEConvertible Security Agreement • February 20th, 2019 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
THIS SENIOR CONVERTIBLE NOTE is a duly authorized and validly issued Senior Convertible Note (this “Note”) of AzurRx BioPharma, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 760 Parkside Avenue, Suite 304 Brooklyn, New York 11226 pursuant to that certain Note Purchase Agreement, dated February 14, 2019, by and between the Company and the Holder (as hereinafter defined), as amended, modified or supplemented from time to time in accordance with its terms (the “Purchase Agreement”).
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • May 13th, 2024 • First Wave BioPharma, Inc. • Pharmaceutical preparations • New York
12% SENIOR SECURED ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE DUE NOVEMBER 11, 2017Convertible Security Agreement • April 12th, 2017 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • Illinois
THIS 12% SENIOR SECURED ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE is a duly authorized and validly issued Senior Secured Original Issue Discount Convertible Debenture (this “Debenture”) of AzurRx BioPharma, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 760 Parkside Avenue, Downstate Biotechnology Incubator, Suite 217 Brooklyn, NY 11226 pursuant to that certain Securities Purchase Agreement, dated April 11, 2017, by and between the Company and Lincoln Park Capital Fund, LLC as amended, modified or supplemented from time to time in accordance with its terms (the “Purchase Agreement”).
UNDERWRITING AGREEMENT among AZURRX BIOPHARMA, INC. and WALLACHBETH Capital, LLC and NETWORK 1 FINANCIAL SECURITIES, INC.,Underwriting Agreement • October 5th, 2016 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
The undersigned, AzurRx BioPharma, Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) and set forth on Schedule 4 attached hereto, as being subsidiaries or affiliates of AzurRx BioPharma, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the Underwriters named in Schedule I hereto (the “Representatives” and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
FIRST WAVE BIOPHARMA, INC. and COLONIAL STOCK TRANSFER CO., INC. as Warrant Agent Warrant Agency Agreement Dated as of December [ ], 2023 WARRANT AGENCY AGREEMENTWarrant Agency Agreement • December 27th, 2023 • First Wave BioPharma, Inc. • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT, dated as of December [ ], 2023 (“Agreement”), between First Wave BioPharma, Inc., a Delaware corporation (the “Company”), and Colonial Stock Transfer Co., Inc. (the “Warrant Agent”).
SERIES A COMMON STOCK PURCHASE WARRANT AZURRX BIOPHARMA, INC.Securities Agreement • June 9th, 2017 • AzurRx BioPharma, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on December 31, 2017 (the “Termination Date”) but not thereafter, to subscribe for and purchase from AzurRx BioPharma, Inc., a Delaware corporation (the “Company”), up to [_____] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
AT THE MARKET OFFERING AGREEMENT May 26, 2021At the Market Offering Agreement • May 26th, 2021 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
AzurRx BioPharma, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows:
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC.Placement Agent Common Stock Purchase Warrant • September 22nd, 2022 • First Wave BioPharma, Inc. • Pharmaceutical preparations • New York
THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [ ], 2022 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on _______[1] (the “Termination Date”) but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain Engagement Agreement by and between the Company and H.C. Wainwright & Co., LLC, dated as of September 13, 2022.
PURCHASE AGREEMENTPurchase Agreement • November 14th, 2019 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • Illinois
THIS PURCHASE AGREEMENT (the “Agreement”), dated as of November 13, 2019, by and between AZURRX BIOPHARMA, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).
PLACEMENT AGENT SERIES D COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC.Placement Agent Agreement • July 18th, 2022 • First Wave BioPharma, Inc. • Pharmaceutical preparations
THIS PLACEMENT AGENT SERIES D COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Reverse Stock Split Date (as defined below) (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the fifth anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain engagement letter, dated as of June 10, 2022, by and between the Company and H.C. Wainwright &
COMMON STOCK PURCHASE WARRANT AZURRX BIOPHARMA, INC.Common Stock Purchase Agreement • January 4th, 2021 • AzurRx BioPharma, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on __________, 20261 (the “Termination Date”) but not thereafter, to subscribe for and purchase from AzurRx Biopharma, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Form of Representative’s Warrant AgreementRepresentative’s Warrant Agreement • October 16th, 2015 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO [ ] [DATE THAT IS ONE (1) YEAR FROM THE EFFECTIVE DATE OF THE OFFERING]. VOID AFTER 5:00 P.M., EASTERN TIME, [ ] [DATE THAT IS FIVE (5) YEARS FROM THE EFFECTIVE DATE OF THE OFFERING].
UNDERWRITING AGREEMENTUnderwriting Agreement • May 4th, 2018 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
AzurRx BioPharma, Inc., a Delaware corporation (the "Company"), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the "Underwriters"), for whom you are acting as Representative (the "Representative"), an aggregate of 4,160,000 shares (the "Firm Shares") of the Company's common stock, $0.0001 par value per share (the "Common Stock"). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 12th, 2017 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • Illinois
This Securities Purchase Agreement (this “Agreement”) is dated as of April 11, 2017, between AzurRx BioPharma, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature page hereto (the “Purchaser”).
5,000,000 Shares AZURRX BIOPHARMA, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 22nd, 2019 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
AzurRx BioPharma, Inc., a Delaware corporation (the "Company"), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the "Underwriters"), for whom you are acting as Representative (the "Representative"), an aggregate of 5,000,000 shares (the "Firm Shares") of the Company's common stock, $0.0001 par value per share (the "Common Stock"). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 750,000 shares (the "Option Shares") of Common Stock for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the "Shares."
UNDERWRITER COMMON STOCK PURCHASE WARRANT AZURRX BIOPHARMA, INC.Underwriter Common Stock Purchase Warrant • July 27th, 2021 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July 22, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from AzurRx BioPharma, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock, as defined in Section 1 herein. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to the Underwriting Agreement, as defined in Section 1 herein.
THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL,...Purchase Warrant Agreement • August 5th, 2016 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO [ ] [DATE THAT IS 180 DAYS FROM THE EFFECTIVE DATE OF THE OFFERING]. VOID AFTER 5:00 P.M., EASTERN TIME, [ ] [DATE THAT IS FIVE (5) YEARS FROM THE EFFECTIVE DATE OF THE OFFERING].
ENTERO THERAPEUTICS, INC. BOARD OF DIRECTORS AGREEMENTBoard of Directors Agreement • March 7th, 2025 • Entero Therapeutics, Inc. • Pharmaceutical preparations
This BOARD OF DIRECTORS AGREEMENT (the “Agreement”) dated March 6, 2025 and effective as of February 12, 2025 (the “Effective Date”), by and between Entero Therapeutics, Inc. a Delaware corporation (the “Company”), and the undersigned signatory (the “Director”), provides for director services, according to the following terms and conditions:
Entero Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • May 12th, 2025 • Entero Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Entero Therapeutics, Inc., a company incorporated under the law of the State of Delaware (the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters named in Schedule 1 hereto for which WestPark Capital, Inc. (“WestPark”) is acting as representative (in such capacity, the “Representative” and such underwriters, including the Representative, the “Underwriters” and each an “Underwriter”), on the terms and conditions set forth herein.
ContractIndemnification Agreement • May 5th, 2022 • First Wave BioPharma, Inc. • Pharmaceutical preparations • Delaware
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 18th, 2022 • First Wave BioPharma, Inc. • Pharmaceutical preparations • Delaware
This Securities Purchase Agreement (this “Agreement”) is dated as of July 15, 2022, between First Wave BioPharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 22nd, 2022 • First Wave BioPharma, Inc. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of November [●], 2022, by and between First Wave BioPharma, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
AZURRX BIOPHARMA, INC. Warrant To Purchase Common StockSecurity Agreement • July 22nd, 2019 • AzurRx BioPharma, Inc. • Pharmaceutical preparations • New York
AzurRx BioPharma, Inc., a company organized under the laws of Delaware (the "Company"), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ___________, the registered holder hereof or its permitted assigns (the "Holder"), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after July __, 2019 (the “Initial Exercisability Date”), but not after 11:59 p.m., New York time, on July __, 2024 (the “Expiration Date”), _____ fully paid non-assessable shares of Common Stock (as defined below), subject to adjustment as provided herein (the "Warrant Shares"). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this "Warrant"), shall have the meanings set forth in Section 16.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 11th, 2025 • Entero Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Securities Purchase Agreement (this “Agreement”) is dated as of August 9, 2025, between Entero Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each, a “Purchaser” and collectively, the “Purchasers”).